Jennison Associates
PLRX icon

Jennison Associates’s Pliant Therapeutics PLRX Stock Holding History

Jennison Associates’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,824
Closed -$921K – 595
2023
Q2 		$921K Sell
50,824
-1,176,588
-96% -$27.9M ﹤0.01% 498
2023
Q1 		$32.6M Sell
1,227,412
-506,178
-29% -$14.4M 0.03% 256
2022
Q4 		$33.5M Sell
1,733,590
-7,387
-0.4% -$154K 0.03% 249
2022
Q3 		$36.4M Buy
+1,740,977
New +$33.3M 0.04% 224

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Jennison Associates's PLRX Position: Q3 2023 in Review

Jennison Associates sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 50,824 shares — an estimated $921K sold.

Jennison Associates first reported a position in PLRX in Q3 2022 and held it in 4 quarters. The position peaked at $36.4M in Q3 2022. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Jennison Associates reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Jennison Associates sold 50,824 Pliant Therapeutics shares in Q3 2023, an estimated $921K.
  • Jennison Associates first reported a position in Pliant Therapeutics in Q3 2022 and held it in 4 quarters.
  • Jennison Associates's Pliant Therapeutics position peaked at $36.4M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Jennison Associates's 13F filing for Q3 2023, filed 31 Oct 2023.